Consultant-Needed-Insert
X

Find Clinical Drug Pipeline Developments & Deals for Tecovirimat

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Therapeutic Area filter
    Study Phase filter
      Country filter
        News Type filter
          Company filter
            refresh

            Companies By Therapeutic Area Full Screen

            Development Status Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Tecovirimat

            Therapeutic Area: Immunology Product Name: Tpoxx

            Highest Development Status: Discovery Product Type: Small molecule

            Partner/Sponsor/Collaborator: JPEO-CBRND

            Deal Size: $23.0 million Upfront Cash: Undisclosed

            Deal Type: Funding June 15, 2020

            Details:

            Funding will support work necessary to gain a potential label expansion from the U.S. FDA for TPOXX® (tecovirimat) for Post-Exposure Prophylaxis (PEP) in addition to the current approved labeling for the treatment of smallpox.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Tecovirimat

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: BARDA

            Deal Size: $101.3 million Upfront Cash: Undisclosed

            Deal Type: Funding April 29, 2020

            Details:

            Funding is directed towards procurement of oral TPOXX for the treatment of smallpox (tecovirimat).